Wang Yaping, Bi Minghong, Zhang Haoran, Gao Zhenyuan, Zhou Hairong, Chang Shu
Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, P.R. China.
Department of Library, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, P.R. China.
Asia Pac J Clin Oncol. 2017 Oct;13(5):e528-e530. doi: 10.1111/ajco.12648. Epub 2016 Dec 28.
Gastric cancer (GC) is the most common gastrointestinal malignant tumor, with a gradual increasing incidence throughout the world. Mostly GC is diagnosed in its late stage. To date, there is no usable standardized treatment regimen for patients with advanced GC. Apatinib mesylate, small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI), has been approved as third-line treatment for patients with advanced gastric adenocarcinoma in China, October, 2014. Till now, there is no case report about apatinib as first-line treatment for patients with advanced GC in literature. We present an 83-year-old Chinese man with advanced gastric adenocarcinoma, who received apatinib as first-line option and obtained clinical benefit within 2 weeks. The lung metastases disappeared completely and the liver metastases shrank significantly. The patient's progression-free survival was 163 days and overall survival was 201 days. This paper reviews and discusses apatinib as a new targeted drug for patients with advanced GC by comparison with other effective molecular-targeted therapy.
胃癌（GC）是最常见的胃肠道恶性肿瘤，在全球范围内其发病率呈逐渐上升趋势。大多数胃癌在晚期才被诊断出来。迄今为止，对于晚期胃癌患者尚无可用的标准化治疗方案。甲磺酸阿帕替尼是一种小分子血管内皮生长因子受体-2（VEGFR-2）酪氨酸激酶抑制剂（TKI），于2014年10月在中国被批准作为晚期胃腺癌患者的三线治疗药物。到目前为止，文献中尚无关于阿帕替尼作为晚期胃癌患者一线治疗的病例报告。我们报告一名83岁的中国晚期胃腺癌男性患者，他接受阿帕替尼作为一线治疗选择，并在2周内获得了临床获益。肺部转移灶完全消失，肝脏转移灶明显缩小。患者的无进展生存期为163天，总生存期为201天。本文通过与其他有效的分子靶向治疗进行比较，对阿帕替尼作为晚期胃癌患者的新型靶向药物进行综述和讨论。
